3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase EARLY_PHASE1
1
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
1
Sarcoma
1
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Interventions
Cisplatin
62
Carboplatin
52
Paclitaxel
49
Radiotherapy
47
Docetaxel
42
Gemcitabine
38
Cyclophosphamide
36
Rituximab
33
Capecitabine
28
Fluorouracil
27
Dexamethasone
27
Doxorubicin
26
Prednisone
21
Bevacizumab
20
Pemetrexed
19
Oxaliplatin
18
Leucovorin
18
pembrolizumab
17
Vincristine
17
Etoposide
17
Cytarabine
15
Imatinib Mesylate
14
Drug Therapy
14
Irinotecan
13
Filgrastim
13
Zoledronic Acid
12
Trastuzumab
12
Radiosurgery
12
Erlotinib Hydrochloride
12
Goserelin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Terminated
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts